Stay informed on the latest Truth Social posts from Donald Trump (@realDonaldTrump) without the doomscrolling. Consider it a public service for your mental health. (Why?)
Filtering by entity: Drug manufacturers | Clear Filter
Summary:A White House letter from July 31, 2025, addresses Novartis regarding an Executive Order from May 12, 2025, to implement Most-Favored-Nation (MFN) prescription drug pricing for American patients. The letter states that U.S. drug prices are up to three times higher than in other developed nations due to global freeloading and directs Novartis and other manufacturers to take specific actions within 60 days, including extending MFN pricing to Medicaid, guaranteeing MFN pricing for newly-launched drugs across all payers, returning increased revenues from abroad, and allowing direct purchasing at MFN rates. It warns that if manufacturers do not cooperate, the administration will deploy every tool to protect American families from abusive pricing, demanding binding commitments by September 29, 2025.
Sentiment:Directive
Key Claims:
- An Executive Order was signed on May 12, 2025, to establish Most-Favored-Nation (MFN) prescription drug pricing for American patients.
- Brand name drug prices in the United States are up to three times higher than in other developed nations due to global freeloading.
- Drug manufacturers, including Novartis, are directed to implement specific actions within 60 days.
- These actions include extending MFN pricing to Medicaid, guaranteeing MFN pricing for newly-launched drugs across all payers, repatriating increased revenues from abroad to American patients, and enabling direct purchasing at MFN rates.
- The administration will deploy "every tool" to combat abusive drug pricing if cooperation is not met.
- Binding commitments for these goals are required by September 29, 2025.
Potential Market Impact (S&P 500):8/10
Potential Geopolitical Risk:2/10
Potential Global Cross-Asset Impact:7/10
Summary:A letter from The White House, dated July 31, 2025, to Pfizer CEO Albert Bourla, outlines an Executive Order signed on May 12, 2025, aimed at ending high drug prices in the United States by mandating Most-Favored-Nation pricing for all drugs for American patients, and warns of consequences if drug manufacturers do not comply within 60 days.
Sentiment:Authoritative Directive
Key Claims:
- An Executive Order was signed on May 12, 2025, to implement Most-Favored-Nation (MFN) drug pricing for American patients.
- American drug prices are up to three times higher than in other developed nations due to 'global freeloading'.
- The Administration demands Pfizer and all drug manufacturers extend MFN pricing to Medicaid patients for existing drugs.
- The Administration demands Pfizer and all drug manufacturers guarantee MFN pricing for newly-launched drugs for all payers.
- The Administration demands increased revenues from abroad be repatriated to lower US drug prices.
- The Administration demands participation in direct purchasing models at MFN pricing.
- Non-compliance will result in the deployment of 'every tool in our arsenal' to protect American families.
- Binding commitments are expected by September 29, 2025.
Potential Market Impact (S&P 500):7/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:5/10
Summary:The White House, on July 31, 2025, sent a letter to Novo Nordisk, outlining an Executive Order signed on May 12, 2025, that mandates drug manufacturers adopt Most-Favored-Nation (MFN) pricing for American patients, including for existing drugs via Medicaid and for new drugs for all payers. The letter claims that American patients currently pay up to three times more for brand-name drugs due to global freeloading and demands that increased revenues from higher prices charged abroad be repatriated to benefit American patients and taxpayers. It instructs manufacturers to implement direct purchasing at MFN pricing and warns that non-compliance by September 29, 2025, will result in the deployment of every available tool.
Sentiment:Directive
Key Claims:
- An Executive Order, 'Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients,' was signed on May 12, 2025.
- Brand name drug prices in the United States are up to three times higher than in other developed nations due to 'global freeloading.'
- Drug manufacturers must extend Most-Favored-Nation (MFN) pricing to Medicaid for their full portfolio of existing drugs.
- Drug manufacturers must guarantee MFN pricing for newly-launched drugs to Medicare, Medicaid, and commercial payers.
- Increased revenues obtained abroad must be repatriated to lower drug prices for American patients and taxpayers.
- Manufacturers must provide for direct purchasing at MFN pricing through Direct-to-Consumer (DTC) and/or Direct-to-Business (DTB) distribution models for high-volume, high-rebate prescription drugs.
- Refusal to comply will result in the deployment of 'every tool in our arsenal to protect American families from continued abusive drug pricing practices.'
- Binding commitments to achieve these goals are required by September 29, 2025.
- Secretary Kennedy and Administrator Oz are part of the team ready to implement these terms.
Potential Market Impact (S&P 500):7/10
Potential Geopolitical Risk:1/10
Potential Global Cross-Asset Impact:6/10
« Previous
Page 1 of 1
Next »